

Eiji Oki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7067837/publications.pdf>

Version: 2024-02-01

399
papers

8,664
citations

44069

48
h-index

79698

73
g-index

412
all docs

412
docs citations

412
times ranked

12565
citing authors

#	ARTICLE	IF	CITATIONS
1	The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells. <i>Cancer Reports</i> , 2022, 5, e1420.	1.4	6
2	Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. <i>Gastric Cancer</i> , 2022, 25, 180-187.	5.3	10
3	Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 37-45.	2.4	9
4	Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study. <i>Esophagus</i> , 2022, 19, 57-68.	1.9	4
5	Clinical impact of the triple-layered circular stapler for reducing the anastomotic leakage in rectal cancer surgery: Porcine model and multicenter retrospective cohort analysis. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 256-264.	2.4	8
6	DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. <i>Cancer Science</i> , 2022, 113, 1531-1534.	3.9	6
7	Tumor progression by epithelial-mesenchymal transition in ARID1A- and SMARCA4-aberrant solid-type poorly differentiated gastric adenocarcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1063-1075.	2.8	4
8	Cancer-derived cholesterol sulfate is a key mediator to prevent tumor infiltration by effector T cells. <i>International Immunology</i> , 2022, 34, 277-289.	4.0	12
9	A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS215-TPS215.	1.6	3
10	Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA (ctDNA) on recurrence in resected colorectal cancer: Initial report of a prospective ctDNA monitoring study COSMOS-CRC-01.. <i>Journal of Clinical Oncology</i> , 2022, 40, 168-168.	1.6	4
11	Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 87-87.	1.6	1
12	Efficacy and safety of neoadjuvant chemotherapy for locally advanced gastric cancer in elderly patients: A phase II trial (KSCC1801).. <i>Journal of Clinical Oncology</i> , 2022, 40, 254-254.	1.6	0
13	Geriatric-8 (G8) screening tool stratified the efficacy of S-1 plus ramucirumab in elderly patients with advanced/recurrent gastric cancer: A post-hoc analysis of the KSCC1701 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 256-256.	1.6	1
14	Plasma-informed minimal residual disease (MRD) assay: A multicenter prospective study in Japanese patients with stage II colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 161-161.	1.6	1
15	Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 126-136.	1.4	1
16	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. <i>JCO Precision Oncology</i> , 2022, 6, e2100383.	3.0	8
17	Three-dimensional imaging of intramural perineural invasion in colorectal cancer: Three-dimensional reconstruction approach with multiple immunohistochemically stained sections. <i>Pathology International</i> , 2022, 72, 293-299.	1.3	2
18	CD44v3,8 is essential for Slug-dependent vimentin gene expression to acquire TGF β 1-induced tumor cell motility. <i>Cancer Science</i> , 2022, 113, 2654-2667.	3.9	4

#	ARTICLE	IF	CITATIONS
19	A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701. <i>European Journal of Cancer</i> , 2022, 166, 279-286.	2.8	2
20	Influence of Robotic Rectal Resection Versus Laparoscopic Rectal Resection on Postoperative Ileus: A Single-center Experience. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2022, Publish Ahead of Print, .	0.8	0
21	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100535.	3.0	29
22	Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. <i>Targeted Oncology</i> , 2022, , 1.	3.6	1
23	Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3419-3429.	1.6	12
24	Impact of the suboptimal communication network environment on telerobotic surgery performance and surgeon fatigue. <i>PLoS ONE</i> , 2022, 17, e0270039.	2.5	8
25	Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4086-4086.	1.6	0
26	Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA1-LBA1.	1.6	52
27	VOYAGER (KSCC1902): A single-arm, multicenter, phase II study of early induction of nivolumab during second-line treatment with taxane ± ramucirumab for advanced gastric or gastro-esophageal junction cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4028-4028.	1.6	0
28	Continuous formation of small clusters with LGR5-positive cells contributes to tumor growth in a colorectal cancer xenograft model. <i>Laboratory Investigation</i> , 2021, 101, 12-25.	3.7	2
29	Comparison of Inflammation-Based Prognostic Scores Associated with the Prognostic Impact of Adenocarcinoma of Esophagogastric Junction and Upper Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2059-2067.	1.5	26
30	Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses. <i>International Journal of Cancer</i> , 2021, 148, 1260-1275.	5.1	4
31	Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial. <i>Cancer Medicine</i> , 2021, 10, 454-461.	2.8	14
32	Comprehensive molecular profiling broadens treatment options for breast cancer patients. <i>Cancer Medicine</i> , 2021, 10, 529-539.	2.8	23
33	Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. <i>Clinical Colorectal Cancer</i> , 2021, 20, e129-e138.	2.3	2
34	Quadruple gastrointestinal cancer with discordance of mismatch repair protein deficiency and microsatellite instability suggesting Lynch syndrome. <i>International Cancer Conference Journal</i> , 2021, 10, 2-5.	0.5	1
35	Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 46-59.	2.4	25
36	FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 314-322.	3.9	8

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of S-1 plus oxaliplatin 130Âmg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A). <i>International Journal of Clinical Oncology</i> , 2021, 26, 345-354.	2.2	1
38	Gastric glomus tumor with a preoperative diagnosis by endoscopic ultrasonography-guided fine needle aspiration: a case report. <i>International Cancer Conference Journal</i> , 2021, 10, 35-40.	0.5	9
39	Indications for laparoscopic surgery for older rectal cancer patients with comorbidities. <i>Surgery Today</i> , 2021, 51, 721-726.	1.5	2
40	Late recurrence of cancer stem cell-positive colorectal cancer liver metastases after 15Âyears. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 613-616.	0.8	1
41	PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> (<i>KRAS/NRAS</i>) wild-type metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 85-85.	1.6	6
42	Characteristics of genomic alterations in circulating tumor DNA (ctDNA) in patients (Pts) with advanced gastrointestinal (GI) cancers in nationwide large-scale ctDNA screening:SCRUM-Japan Monstar-Screen.. <i>Journal of Clinical Oncology</i> , 2021, 39, 106-106.	1.6	3
43	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 631-641.	1.6	63
44	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , 2021, 27, 2515-2522.	7.0	39
45	Realâ€world data on microsatellite instability status in various unresectable or metastatic solid tumors. <i>Cancer Science</i> , 2021, 112, 1105-1113.	3.9	73
46	Recent developments in cancer research: Expectations for a new remedy. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 419-426.	2.4	12
47	Mutational signatures in squamous cell carcinoma of the lung. <i>Journal of Thoracic Disease</i> , 2021, 13, 1075-1082.	1.4	4
48	Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer. <i>Cancer Medicine</i> , 2021, 10, 3129-3138.	2.8	21
49	ASO Author Reflection: Radiomics-Based Prediction for the Responder to First-Line Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastasis. <i>Annals of Surgical Oncology</i> , 2021, 28, 2986-2987.	1.5	2
50	Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. <i>Journal of Gastroenterology</i> , 2021, 56, 547-559.	5.1	23
51	A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4043-4043.	1.6	0
52	Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen species accumulation. <i>Gastric Cancer</i> , 2021, 24, 1089-1099.	5.3	14
53	Feasibility of hepatic resection for liver metastasis of head-and-neck carcinoma or esophageal carcinoma: a multi-center experience. <i>Surgery Today</i> , 2021, 51, 1932-1937.	1.5	2
54	Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 780-789.	5.3	24

#	ARTICLE	IF	CITATIONS
55	Measurement of circumferential tumor extent of colorectal cancer on CT colonography: relation to clinicopathological features and patient prognosis after surgery. <i>Japanese Journal of Radiology</i> , 2021, 39, 966-972.	2.4	3
56	Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first-line treatment. <i>Cancer Science</i> , 2021, 112, 2436-2441.	3.9	2
57	Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study. <i>Investigational New Drugs</i> , 2021, 39, 1649-1655.	2.6	3
58	Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3608-3608.	1.6	5
59	Pre-treatment status of inflammation-based biomarkers in the patients with advanced gastric cancer who will be treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16107-e16107.	1.6	0
60	Histological categorisation of the desmoplastic reaction is a predictor of patient prognosis in oesophageal squamous cell carcinoma. <i>Histopathology</i> , 2021, 79, 219-226.	2.9	9
61	Impact of a metastatic site on circulating tumor DNA (ctDNA) analysis in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3554-3554.	1.6	11
62	Clinical significance of signal regulatory protein alpha (SIRP α) expression in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2021, 112, 3018-3028.	3.9	16
63	REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 674.	2.6	19
64	CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. <i>Cancer Science</i> , 2021, 112, 2915-2920.	3.9	74
65	Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1459-1463.	0.8	4
66	Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	7.0	27
67	Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2025-2028.	2.2	3
68	Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancer. <i>Scientific Reports</i> , 2021, 11, 19178.	3.3	10
69	Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. <i>Clinical Colorectal Cancer</i> , 2021, 20, e173-e184.	2.3	7
70	Radiomics Texture Analysis for the Identification of Colorectal Liver Metastases Sensitive to First-Line Oxaliplatin-Based Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 2975-2985.	1.5	19
71	Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301). <i>BMC Cancer</i> , 2021, 21, 23.	2.6	8
72	Cancer-associated Fibroblast-derived Spondin-2 Promotes Motility of Gastric Cancer Cells. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 521-529.	2.0	9

#	ARTICLE	IF	CITATIONS
73	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4019.	1.6	45
74	Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients. <i>BMC Cancer</i> , 2021, 21, 1332.	2.6	2
75	The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. <i>Cancer Science</i> , 2021, , .	3.9	2
76	Skeletal Muscle Loss After Esophagectomy Is an Independent Risk Factor for Patients with Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 492-498.	1.5	28
77	Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 614-621.	2.2	13
78	Changing the Dissectable Layer: Novel Thoracoscopic Esophagectomy Method for Lymphadenectomy along the Left Recurrent Laryngeal Nerve. <i>Journal of the American College of Surgeons</i> , 2020, 230, e1-e6.	0.5	5
79	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 217-223.	2.3	13
80	Autocrine Leukemia Inhibitory Factor Promotes Esophageal Squamous Cell Carcinoma Progression via Src Family Kinase-Dependent Yes-Associated Protein Activation. <i>Molecular Cancer Research</i> , 2020, 18, 1876-1888.	3.4	5
81	RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	7
82	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864.	30.7	209
83	Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). <i>Oncologist</i> , 2020, 25, e1855-e1863.	3.7	28
84	Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 1116.	2.6	2
85	New Anastomosis Technique to Prevent Anastomotic Leakage in Laparoscopic Anterior Resection for Rectal Cancer, Especially Upper Rectal Cancer. <i>In Vivo</i> , 2020, 34, 3533-3538.	1.3	3
86	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 Td <i>Lancet Oncology</i> , The, 2020, 21, 1620-1629.	10.7	152
87	CTDSP1 inhibitor rabepazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer. <i>PLoS ONE</i> , 2020, 15, e0228002.	2.5	9
88	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 687.	2.6	9
89	A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401). <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 285-294.	2.3	2
90	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. <i>Gastroenterology</i> , 2020, 159, 2146-2162.e33.	1.3	75

#	ARTICLE	IF	CITATIONS
91	Obstructive rectal endometriosis treated by robot-assisted laparoscopic surgery: a case report. <i>Surgical Case Reports</i> , 2020, 6, 211.	0.6	0
92	A rare case of esophageal adenocarcinoma with urinary bladder metastasis. <i>International Cancer Conference Journal</i> , 2020, 9, 231-234.	0.5	0
93	Thoracoscopic esophagectomy in total pharyngolaryngoesophagectomy for esophageal cancer; A case series. <i>Annals of Medicine and Surgery</i> , 2020, 60, 9-13.	1.1	2
94	Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report. <i>International Cancer Conference Journal</i> , 2020, 9, 127-132.	0.5	3
95	DNA Replication Stress Induced by Trifluridine Determines Tumor Cell Fate According to p53 Status. <i>Molecular Cancer Research</i> , 2020, 18, 1354-1366.	3.4	10
96	Factors of incomplete colonoscopy for stenosing colorectal cancer: CT colonography features. <i>Japanese Journal of Radiology</i> , 2020, 38, 973-978.	2.4	4
97	Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1115-1122.	2.2	3
98	Identification of characteristic compounds of moderate volatility in breast cancer cell lines. <i>PLoS ONE</i> , 2020, 15, e0235442.	2.5	4
99	Primary anorectal malignant melanoma with laparoscopic abdominoperineal resection: a case study and review of the relevant literature. <i>International Cancer Conference Journal</i> , 2020, 9, 116-122.	0.5	1
100	Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603). <i>Oncology</i> , 2020, 98, 719-726.	1.9	0
101	Solid-type poorly differentiated adenocarcinoma of the stomach: Deficiency of mismatch repair and SWI/SNF complex. <i>Cancer Science</i> , 2020, 111, 1008-1019.	3.9	14
102	Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1318-1326.	2.2	20
103	Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1029-1038.	2.3	6
104	A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier. <i>Oncology</i> , 2020, 98, 534-541.	1.9	8
105	Potential association of LOXL1 with peritoneal dissemination in gastric cancer possibly via promotion of EMT. <i>PLoS ONE</i> , 2020, 15, e0241140.	2.5	13
106	Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer. <i>Surgical Case Reports</i> , 2020, 6, 298.	0.6	6
107	Title is missing!. , 2020, 15, e0228002.		0
108	Title is missing!. , 2020, 15, e0228002.		0

#	ARTICLE	IF	CITATIONS
109	Title is missing!. , 2020, 15, e0228002.		0
110	Title is missing!. , 2020, 15, e0228002.		0
111	Title is missing!., 2020, 15, e0228002.		0
112	Title is missing!. , 2020, 15, e0228002.		0
113	Amide proton transfer imaging to predict tumor response to neoadjuvant chemotherapy in locally advanced rectal cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 140-146.	2.8	28
114	Câ€reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 355-363.	2.8	44
115	Postoperative development of sarcopenia is a strong predictor of a poor prognosis in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer. <i>American Journal of Surgery</i> , 2019, 217, 757-763.	1.8	35
116	Successful multidisciplinary treatment including repeated metastasectomy for recurrent squamous cell esophageal carcinoma: a case report. <i>Surgical Case Reports</i> , 2019, 5, 72.	0.6	1
117	Principles and development of collagen-mediated tissue fusion induced by laser irradiation. <i>Scientific Reports</i> , 2019, 9, 9383.	3.3	8
118	Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). <i>British Journal of Cancer</i> , 2019, 121, 222-229.	6.4	37
119	Intestinal Behçetâ€™s Disease with Primary Myelofibrosis Involving Trisomy 8. <i>Acta Haematologica</i> , 2019, 142, 253-256.	1.4	4
120	Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1397-1405.	2.2	0
121	Exploration of potential prognostic biomarkers in aflibercept plus <scp>FOLFIRI</scp> in Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2019, 110, 3565-3572.	3.9	11
122	Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1574.	7.1	74
123	The evolution of surgical treatment for gastrointestinal cancers. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1333-1349.	2.2	7
124	Postoperative Skeletal Muscle Loss Predicts Poor Prognosis of Adenocarcinoma of Upper Stomach and Esophagogastric Junction. <i>World Journal of Surgery</i> , 2019, 43, 1068-1075.	1.6	14
125	CT gastrography â€œwall-carving techniqueâ€œof gastric cancer: impact of contrast enhancement based on layer depth. <i>Japanese Journal of Radiology</i> , 2019, 37, 597-604.	2.4	4
126	Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level. <i>Scientific Reports</i> , 2019, 9, 7964.	3.3	13

#	ARTICLE	IF	CITATIONS
127	Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A). <i>International Journal of Clinical Oncology</i> , 2019, 24, 1204-1213.	2.2	27
128	Efficacy of Novel Multispectral Imaging Device to Determine Anastomosis for Esophagogastrostomy. <i>Journal of Surgical Research</i> , 2019, 242, 11-22.	1.6	12
129	A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 982-986.	6.4	64
130	Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2019, 110, 1032-1043.	3.9	30
131	Short- and Long-term Outcomes of Surgical Treatment for Remnant Gastric Cancer After Distal Gastrectomy. <i>Anticancer Research</i> , 2019, 39, 1411-1415.	1.1	6
132	Primary amelanotic malignant melanoma of the esophagus: a case report. <i>Surgical Case Reports</i> , 2019, 5, 4.	0.6	9
133	Gastric hepatoid adenocarcinomas are a genetically heterogeneous group; most tumors show chromosomal instability, but MSI tumors do exist. <i>Human Pathology</i> , 2019, 88, 27-38.	2.0	19
134	Sarcopenia discriminates poor prognosis in elderly patients following emergency surgery for perforation peritonitis. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 630-637.	2.4	7
135	The balance of forces generated by kinesins controls spindle polarity and chromosomal heterogeneity in tetraploid cells. <i>Journal of Cell Science</i> , 2019, 132, .	2.0	8
136	Recent Incidence Trend of Surgically Resected Esophagogastric Junction Adenocarcinoma and Microsatellite Instability Status in Japanese Patients. <i>Digestion</i> , 2019, 99, 6-13.	2.3	32
137	Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 465-472.	1.5	32
138	Effect of lateral lymph node dissection for mid and low rectal cancer: An ad-hoc analysis of the ACTS-RC (JFMC35-C1) randomized clinical trial. <i>Surgery</i> , 2019, 165, 586-592.	1.9	16
139	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	5.3	60
140	Trifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A multicenter, phase II clinical trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3548-3548.	1.6	5
141	Retrospective multicenter study for assessment of association between imaging change and outcome after treatment of regorafenib: KSCC1603. <i>Journal of Clinical Oncology</i> , 2019, 37, 509-509.	1.6	1
142	Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN. <i>Journal of Clinical Oncology</i> , 2019, 37, 578-578.	1.6	1
143	Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study. <i>Journal of Clinical Oncology</i> , 2019, 37, 624-624.	1.6	1
144	MSI-low is an intermediate type between MSI-high and MSS in esophagogastric junction adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 44-44.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA.. Journal of Clinical Oncology, 2019, 37, 3528-3528.	1.6	3
146	Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 3560-3560.	1.6	1
147	Efficacy and safety of nivolumab monotherapy as the late line for patients with advanced gastric cancer in the real-world.. Journal of Clinical Oncology, 2019, 37, e14074-e14074.	1.6	0
148	Epithelial Paradox: Clinical Significance of Coexpression of E-cadherin and Vimentin WithÂ REGARD to Invasion and Metastasis of BreastÂ Cancer. Clinical Breast Cancer, 2018, 18, e1003-e1009.	2.4	64
149	A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. Clinical Colorectal Cancer, 2018, 17, 147-155.	2.3	35
150	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). Oncology, 2018, 94, 289-296.	1.9	5
151	Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?. World Journal of Surgery, 2018, 42, 2894-2901.	1.6	25
152	Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung. Annals of Surgical Oncology, 2018, 25, 1564-1571.	1.5	23
153	Recent advances in treatment for colorectal liver metastasis. Annals of Gastroenterological Surgery, 2018, 2, 167-175.	2.4	36
154	Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors. Journal of Histochemistry and Cytochemistry, 2018, 66, 549-561.	2.5	4
155	A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. European Journal of Cancer, 2018, 91, 86-91.	2.8	48
156	Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. Scientific Reports, 2018, 8, 1005.	3.3	22
157	Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 745-753.	1.5	40
158	DNA replication stress and cancer chemotherapy. Cancer Science, 2018, 109, 264-271.	3.9	80
159	Effect of early oral feeding on length of hospital stay following gastrectomy for gastric cancer: a Japanese multicenter, randomized controlled trial. Surgery Today, 2018, 48, 865-874.	1.5	35
160	Laparoscopic Proximal Gastrectomy Maintains Body Weight and Skeletal Muscle Better Than Total Gastrectomy. World Journal of Surgery, 2018, 42, 3270-3276.	1.6	41
161	Sarcopenia is an independent predictor of complications after colorectal cancer surgery. Surgery Today, 2018, 48, 151-157.	1.5	118
162	Clinical significance of programmed cell deathâ€ ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. International Journal of Cancer, 2018, 142, 822-832.	5.1	55

#	ARTICLE	IF	CITATIONS
163	Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency. <i>American Journal of Surgical Pathology</i> , 2018, 42, 172-182.	3.7	16
164	A novel histological examination with dynamic three-dimensional reconstruction from multiple immunohistochemically stained sections of a PD-L1-positive colon cancer. <i>Histopathology</i> , 2018, 72, 697-703.	2.9	12
165	Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e643-e650.	2.4	5
166	Energy-less technique with mini-clips for recurrent laryngeal nerve lymph node dissection in prone thoracoscopic esophagectomy for esophageal cancer. <i>American Journal of Surgery</i> , 2018, 216, 1212-1214.	1.8	5
167	Non-familial juvenile polyposis of the stomach with gastric cancers: a case report. <i>Surgical Case Reports</i> , 2018, 4, 79.	0.6	4
168	CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 6258-6268.	2.8	22
169	BUBR1 Insufficiency Is Correlated with eNOS Reduction Experimentally In Vitro and In Vivo, and in Gastric Cancer Tissue. <i>Anticancer Research</i> , 2018, 38, 6099-6106.	1.1	5
170	Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 6809-6814.	1.1	15
171	Effect of age factors on health-related quality of life in patients with lower rectal cancer after sphincter-saving surgery: A 1-year longitudinal study. <i>Archives of Gerontology and Geriatrics</i> , 2018, 79, 185-191.	3.0	2
172	Gastric cancer with synchronous and metachronous hepatic metastasis predicted by enhancement pattern on multiphasic contrast-enhanced CT. <i>European Journal of Radiology</i> , 2018, 108, 165-171.	2.6	6
173	Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to Trastuzumab (KSCC1604). <i>European Journal of Cancer</i> , 2018, 105, 41-49.	2.8	58
174	Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer. <i>In Vivo</i> , 2018, 32, 1491-1498.	1.3	8
175	Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. <i>ESMO Open</i> , 2018, 3, e000411.	4.5	13
176	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. <i>Nature Medicine</i> , 2018, 24, 968-977.	30.7	196
177	Amide proton transfer imaging can predict tumor grade in rectal cancer. <i>Magnetic Resonance Imaging</i> , 2018, 51, 96-103.	1.8	35
178	Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin+S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy. <i>BMC Cancer</i> , 2018, 18, 57.	2.6	1
179	A case of mixed adenoneuroendocrine carcinoma (MANEC) arising in Barrett's esophagus: literature and review. <i>Surgical Case Reports</i> , 2018, 4, 45.	0.6	15
180	Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. <i>Surgical Oncology</i> , 2018, 27, 637-641.	1.6	10

#	ARTICLE	IF	CITATIONS
181	Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e687-e697.	2.3	15
182	Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity. <i>Molecular Cancer Research</i> , 2018, 16, 1483-1490.	3.4	12
183	REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecanâ€”Biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3510-3510.	1.6	5
184	APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3523-3523.	1.6	7
185	A validation study of stratification by the 55-gene classifier for assessing recurrence risk in stage II colon cancer: The 55 STAR study (UMIN23879).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3526-3526.	1.6	1
186	Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4038-4038.	1.6	4
187	Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells. <i>Oncotarget</i> , 2018, 9, 17620-17630.	1.8	9
188	Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. <i>Oncotarget</i> , 2018, 9, 37216-37228.	1.8	24
189	Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2018, 38, 491-499.	1.1	8
190	Gastric Cancer of "Crawling Type" Detected by Additional Gastrectomy After Endoscopic Submucosal Resection. <i>Anticancer Research</i> , 2018, 38, 2335-2338.	1.1	1
191	The Clinical Usefulness of the LigaSureâ„¢ Small Jaw in Axillary Lymph Node Dissection in Patients with Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 2359-2362.	1.1	5
192	Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10094-10094.	1.6	0
193	Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. <i>Gastric Cancer</i> , 2017, 20, 175-181.	5.3	77
194	Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan. <i>International Journal of Clinical Oncology</i> , 2017, 22, 505-510.	2.2	2
195	Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 1804-1810.	1.5	91
196	Diffuse-type gastric cancer: specific enhancement pattern on multiphasic contrast-enhanced computed tomography. <i>Japanese Journal of Radiology</i> , 2017, 35, 289-295.	2.4	18
197	Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial. <i>Surgery Today</i> , 2017, 47, 1060-1071.	1.5	19
198	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 158-163.	2.3	13

#	ARTICLE	IF	CITATIONS
199	Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of RhoB, and Ability to Induce Invasiveness of Gastric Cancer Cells. <i>Gastroenterology</i> , 2017, 153, 191-204.e16.	1.3	158
200	Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 753-758.	1.8	12
201	Anal metastasis of rectal cancer—adenocarcinoma of squamous cells: a case report and literature review. <i>Surgical Case Reports</i> , 2017, 3, 55.	0.6	7
202	Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1. <i>Cell Reports</i> , 2017, 19, 969-980.	6.4	51
203	A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). <i>International Journal of Clinical Oncology</i> , 2017, 22, 913-920.	2.2	6
204	High ubiquitin-specific protease 44 expression induces DNA aneuploidy and provides independent prognostic information in gastric cancer. <i>Cancer Medicine</i> , 2017, 6, 1453-1464.	2.8	26
205	Programmed death ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2017, 108, 1119-1127.	3.9	100
206	Prognostic impact of MutT homolog 1 expression on esophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2017, 6, 258-266.	2.8	29
207	Overexpression of CXCR7 Is a Novel Prognostic Indicator in Gastric Cancer. <i>Digestive Surgery</i> , 2017, 34, 312-318.	1.2	17
208	Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 147-153.	2.3	4
209	Histopathologic diversity of gastric cancers: Relationship between enhancement pattern on dynamic contrast-enhanced CT and histological type. <i>European Journal of Radiology</i> , 2017, 97, 90-95.	2.6	26
210	Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. <i>Oncology</i> , 2017, 93, 387-394.	1.9	31
211	The requirement of Mettl3-promoted MyoD mRNA maintenance in proliferative myoblasts for skeletal muscle differentiation. <i>Open Biology</i> , 2017, 7, 170119.	3.6	71
212	Clinical significance of ZNF750 gene expression, a novel tumor suppressor gene, in esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2017, 14, 1795-1801.	1.8	12
213	Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication. <i>Scientific Reports</i> , 2017, 7, 16969.	3.3	8
214	Actionable gene-based classification toward precision medicine in gastric cancer. <i>Genome Medicine</i> , 2017, 9, 93.	8.2	59
215	Successful surgical intervention for rectal perforation due to polyarteritis nodosa: report of a case. <i>Surgical Case Reports</i> , 2017, 3, 43.	0.6	1
216	Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 151-160.	2.5	30

#	ARTICLE	IF	CITATIONS
217	CONUT: a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. <i>International Journal of Colorectal Disease</i> , 2017, 32, 99-106.	2.2	108
218	The Expression of <i>CCAT2</i> , a Novel Long Noncoding RNA Transcript, and rs6983267 Single-Nucleotide Polymorphism Genotypes in Colorectal Cancers. <i>Oncology</i> , 2017, 92, 48-54.	1.9	38
219	Mitotic slippage and the subsequent cell fates after inhibition of Aurora B during tubulin-binding agent-induced mitotic arrest. <i>Scientific Reports</i> , 2017, 7, 16762.	3.3	32
220	Recurrence with pagetoid spread arising 17 years after surgery for intramucosal rectal cancer: a case report. <i>Surgical Case Reports</i> , 2017, 3, 85.	0.6	4
221	Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. <i>Oncotarget</i> , 2017, 8, 93567-93579.	1.8	26
222	Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. <i>Oncotarget</i> , 2017, 8, 107666-107677.	1.8	37
223	Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review. , 2017, 37, 5687-5691.		4
224	Current Treatment and Application of Hyperthermia for Squamous Cell Carcinoma of the Esophagus. <i>Thermal Medicine</i> , 2017, 33, 63-73.	0.1	0
225	A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report. <i>Anticancer Research</i> , 2017, 37, 1917-1921.	1.1	1
226	The clinical impact of the Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score on breast cancer patients survival.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1560-1560.	1.6	0
227	The Local Recurrence of Breast Cancer with Squamous Metaplasia and Obvious Histological Heterogeneity. <i>Anticancer Research</i> , 2017, 37, 5249-5254.	1.1	1
228	Lysine-specific demethylase 1 contributes to malignant behavior by regulation of invasive activity and metabolic shift in esophageal cancer. <i>International Journal of Cancer</i> , 2016, 138, 428-439.	5.1	23
229	Development of fistula between esophagogastric anastomotic site and cartilage portion of trachea after subtotal esophagectomy for cervical esophageal cancer: a case report. <i>Surgical Case Reports</i> , 2016, 2, 107.	0.6	4
230	High expression of the Notch ligand <i>Jagged1</i> is associated with poor prognosis after surgery for colorectal cancer. <i>Cancer Science</i> , 2016, 107, 1705-1716.	3.9	32
231	Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. <i>Genome Medicine</i> , 2016, 8, 136.	8.2	64
232	Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. <i>Cancer Immunology Research</i> , 2016, 4, 520-530.	3.4	79
233	Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes. <i>Medical Oncology</i> , 2016, 33, 118.	2.5	13
234	Diagnosis of early colorectal cancer invasion depth by quantitative evaluation of the basal indentation in CT colonography. <i>Japanese Journal of Radiology</i> , 2016, 34, 786-794.	2.4	2

#	ARTICLE	IF	CITATIONS
235	Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis. <i>Oncology</i> , 2016, 91, 31-40.	1.9	23
236	Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 585-593.	2.3	5
237	Impact of Expression of Vimentin and Axl in Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 520-526.e2.	2.4	31
238	The antibodies against 5-bromo-2-deoxyuridine specifically recognize trifluridine incorporated into DNA. <i>Scientific Reports</i> , 2016, 6, 25286.	3.3	23
239	Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome. <i>Annals of Surgical Oncology</i> , 2016, 23, 508-515.	1.5	49
240	Phosphorylation of EB2 by Aurora B and CDK1 ensures mitotic progression and genome stability. <i>Nature Communications</i> , 2016, 7, 11117.	12.8	34
241	Distant lymph node metastases caused by esophageal cancer invasion to the lamina propria: a case report. <i>Surgical Case Reports</i> , 2016, 2, 143.	0.6	2
242	Clinical Significance of Totally Laparoscopic Distal Gastrectomy: A Comparison of Short-term Outcomes Relative to Open and Laparoscopic-assisted Distal Gastrectomy. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2016, 26, 372-376.	0.8	9
243	12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2906-2913.	1.6	62
244	Induction of potentially lethal hypermagnesemia, ischemic colitis, and toxic megacolon by a preoperative mechanical bowel preparation: report of a case. <i>Surgical Case Reports</i> , 2016, 2, 18.	0.6	8
245	Mixed spindle and epithelioid cell type gastrointestinal stromal tumor of the esophagus: a case report. <i>Esophagus</i> , 2016, 13, 301-305.	1.9	1
246	Real-Time Accurate Identification of Tumor Site Using a Mobile X-Ray Image-Intensifier System During Laparoscopic Gastrectomy. <i>Journal of the American College of Surgeons</i> , 2016, 222, e1-e7.	0.5	4
247	Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer. <i>Breast</i> , 2016, 25, 62-68.	2.2	7
248	Blood Flow Assessment with Indocyanine Green Fluorescence Angiography for Pedicled Omental Flap on Cervical Esophagogastric Anastomosis after Esophagectomy. <i>Journal of the American College of Surgeons</i> , 2016, 222, e67-e69.	0.5	23
249	APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. <i>Medical Oncology</i> , 2016, 33, 26.	2.5	20
250	Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia. <i>Human Pathology</i> , 2016, 52, 145-152.	2.0	11
251	Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1986-1992.	1.5	13
252	S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). <i>International Journal of Clinical Oncology</i> , 2016, 21, 705-712.	2.2	7

#	ARTICLE	IF	CITATIONS
253	Differentiation of early gastric cancer with ulceration and resectable advanced gastric cancer using multiphase dynamic multidetector CT. <i>European Radiology</i> , 2016, 26, 1330-1337.	4.5	41
254	The Prognostic Significance of Histone Lysine Demethylase JMJD3/KDM6B in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 678-685.	1.5	42
255	A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). <i>International Journal of Clinical Oncology</i> , 2016, 21, 335-343.	2.2	10
256	Incidence of Venous Thromboembolism Following Laparoscopic Surgery for Gastrointestinal Cancer: A Single-Center, Prospective Cohort Study. <i>World Journal of Surgery</i> , 2016, 40, 309-314.	1.6	31
257	Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). <i>Gastric Cancer</i> , 2016, 19, 968-976.	5.3	101
258	Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). <i>International Journal of Clinical Oncology</i> , 2016, 21, 110-117.	2.2	3
259	Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. <i>Surgery Today</i> , 2016, 46, 261-267.	1.5	10
260	Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. <i>PLoS Genetics</i> , 2016, 12, e1005778.	3.5	134
261	Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women. <i>PLoS ONE</i> , 2016, 11, e0168090.	2.5	17
262	Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 19748-19761.	1.8	34
263	Laparoscopic Resection of Gastric Cancer in a Patient with Chronic Lymphocytic Leukemia Accompanied by Neutropenia. <i>Anticancer Research</i> , 2016, 36, 1779-83.	1.1	0
264	Conversion to Neuroendocrine Carcinoma from Squamous Cell Carcinoma of the Esophagus After Definitive Chemoradiotherapy. <i>Anticancer Research</i> , 2016, 36, 4045-9.	1.1	8
265	Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer. <i>Cancer Medicine</i> , 2015, 4, 75-83.	2.8	55
266	Intensive Immunofluorescence Staining Methods for Low Expression Protein: Detection of Intestinal Stem Cell Marker LGR5. <i>Acta Histochemica Et Cytochemica</i> , 2015, 48, 159-164.	1.6	6
267	The Use of a Circular Side Stapling Technique in Laparoscopic Low Anterior Resection for Rectal Cancer: Experience of 30 Serial Cases. <i>International Surgery</i> , 2015, 100, 979-983.	0.1	7
268	Long-term treatment with panitumumab monotherapy for recurrent colorectal cancer. <i>International Cancer Conference Journal</i> , 2015, 4, 151-154.	0.5	1
269	Carbohydrate antigen 19 is a useful prognostic marker in esophagogastric junction adenocarcinoma. <i>Cancer Medicine</i> , 2015, 4, 1659-1666.	2.8	26
270	Indocyanine Green Fluorescence Angiography for Quantitative Evaluation of Gastric Tube Perfusion in Patients Undergoing Esophagectomy. <i>Journal of the American College of Surgeons</i> , 2015, 221, e37-e42.	0.5	77

#	ARTICLE	IF	CITATIONS
271	Clinical Significance of SIP1 and E-cadherin in Patients with Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 2608-2614.	1.5	11
272	Evaluation of techniques to prevent colorectal anastomotic leakage. <i>Journal of Surgical Research</i> , 2015, 194, 450-457.	1.6	26
273	Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1004-1013.	4.1	55
274	Esophageal cancer associated with bilateral hilar lymphadenopathy caused by sarcoid-like reactions: a report of two cases. <i>Esophagus</i> , 2015, 12, 322-326.	1.9	4
275	Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 498-504.	2.4	42
276	Recent advances in multidisciplinary approach for rectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 641-649.	2.2	9
277	Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. <i>International Journal of Clinical Oncology</i> , 2015, 20, 767-775.	2.2	78
278	Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation. <i>Annals of Surgical Oncology</i> , 2015, 22, 3659-3665.	1.5	20
279	Loss of Heterozygosity of PTEN (Encoding Phosphate and Tensin Homolog) Associated with Elevated HER2 Expression Is an Adverse Prognostic Indicator in Gastric Cancer. <i>Oncology</i> , 2015, 88, 189-194.	1.9	7
280	SPINK1 Status in Colorectal Cancer, Impact on Proliferation, and Role in Colitis-Associated Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 1130-1138.	3.4	27
281	An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression. <i>Cancer Research</i> , 2015, 75, 4985-4997.	0.9	113
282	Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002). <i>Annals of Surgical Oncology</i> , 2015, 22, 1067-1074.	1.5	16
283	The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2332-2342.	4.1	27
284	Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor. <i>Human Pathology</i> , 2015, 46, 1890-1900.	2.0	79
285	Endoscopic evaluation of clinical colorectal anastomotic leakage. <i>Journal of Surgical Research</i> , 2015, 193, 126-134.	1.6	23
286	Pharyngo-laryngo-esophagectomy and reconstruction with a gastric tube for corrosive pharyngoesophagitis. <i>Esophagus</i> , 2015, 12, 360-364.	1.9	0
287	A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3515-3515.	1.6	1
288	Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. <i>Oncotarget</i> , 2015, 6, 34004-34013.	1.8	13

#	ARTICLE	IF	CITATIONS
289	Rapidly Increased Peritoneal Metastases of Squamous Cell Carcinoma of the Upper Thoracic Esophagus after Preoperative Chemoradiotherapy—A Case Report—. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2015, 76, 2706-2711.	0.0	0
290	A prospective study of XELIRI plus bevacizumab as the first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).. Journal of Clinical Oncology, 2015, 33, 752-752.	1.6	0
291	A prospective study of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).. Journal of Clinical Oncology, 2015, 33, 129-129.	1.6	0
292	Liver resectability following S-1+L-OHP with cetuximab as the first-line treatment of unresectable liver limited metastases from KRAS exon 2 wild-colorectal cancer in Japanese patients (KSCC 1002).. Journal of Clinical Oncology, 2015, 33, 755-755.	1.6	2
293	Validation of postoperative adjuvant chemotherapy for elderly patients with stage II/III gastric cancer.. Journal of Clinical Oncology, 2015, 33, e15036-e15036.	1.6	0
294	A central review of liver resectability and pathological tumor response after chemotherapy in patients with initially unresectable colorectal cancer liver metastases: Phase II trials of mFOLFOX6 plus bevacizumab (KSCC0802), and SOX (S-1 and oxaliplatin) plus cetuximab (KSCC1002).. Journal of Clinical Oncology, 2015, 33, e14548-e14548.	1.6	0
295	Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. Anticancer Research, 2015, 35, 401-6.	1.1	14
296	Cardiac tamponade due to bleeding as a potential lethal complication after surgery for esophageal cancer. Anticancer Research, 2015, 35, 407-11.	1.1	3
297	Assessment of surgical treatment and postoperative nutrition in gastric cancer patients older than 80 years. Anticancer Research, 2015, 35, 511-5.	1.1	6
298	Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy. Anticancer Research, 2015, 35, 2299-303.	1.1	10
299	Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. Anticancer Research, 2015, 35, 2441-6.	1.1	17
300	Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report. Anticancer Research, 2015, 35, 4037-41.	1.1	12
301	Suppressor microRNA-145 Is Epigenetically Regulated by Promoter Hypermethylation in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2015, 35, 4617-24.	1.1	18
302	Laparoscopic Total Gastrectomy for RGC: Four Case Reports. Anticancer Research, 2015, 35, 5023-6.	1.1	4
303	Number of Lymph Node Metastases May Indicate the Regimen for Adjuvant Chemotherapy in Patients with Stage III Colorectal Cancer. Anticancer Research, 2015, 35, 6207-11.	1.1	1
304	One-stage Procedure for Concomitant Abdominal Aortic Aneurysm and Gastric Cancer. Anticancer Research, 2015, 35, 6909-12.	1.1	2
305	IgG4-related disease of the ileocecal region mimicking malignancy: A case report. International Journal of Surgery Case Reports, 2014, 5, 669-672.	0.6	57
306	Contribution of Aurora-A and -B expression to DNA aneuploidy in gastric cancers. Surgery Today, 2014, 44, 454-461.	1.5	27

#	ARTICLE	IF	CITATIONS
307	Mortalin is a prognostic factor of gastric cancer with normal p53 function. <i>Gastric Cancer</i> , 2014, 17, 255-262.	5.3	43
308	Simultaneous resection of colorectal cancer and liver metastases in the right lobe using pure laparoscopic surgery. <i>Surgery Today</i> , 2014, 44, 1588-1592.	1.5	4
309	Technical Improvement of Total Pharyngo-Laryngo-Esophagectomy for Esophageal Cancer and Head and Neck Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 1671-1677.	1.5	26
310	Pure laparoscopic right-sided hepatectomy in the semi-prone position for synchronous colorectal cancer with liver metastases. <i>Asian Journal of Endoscopic Surgery</i> , 2014, 7, 133-137.	0.9	10
311	Book-Binding Technique for Billroth I Anastomosis During Totally Laparoscopic Distal Gastrectomy. <i>Journal of the American College of Surgeons</i> , 2014, 219, e69-e73.	0.5	12
312	Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 2340-2346.	1.5	35
313	Two Cases of Advanced Gastric Cancer Showing Multiple Liver Metastases Diagnosed with Paraneoplastic Syndrome. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2014, 39, 900-905.	0.0	1
314	A Case of Curatively Resected Rectal Cancer with Liver Metastasis and Bladder Invasion Responding to IRIS+Cam Mab. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2014, 39, 734-738.	0.0	0
315	Changes in expression levels of excision repair cross-complementing group 1 (ERCC1) and dihydropyrimidine dehydrogenase (DPD) after first-line oxaliplatin-based chemotherapy for metastatic colorectal cancer: Results of a multicenter study. <i>Journal of Clinical Oncology</i> , 2014, 32, 463-463.	1.6	0
316	Relationship of global DNA hypomethylation-mediated chromosomal instability to the initiation and progression of esophageal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e15011-e15011.	1.6	0
317	Trastuzumab plus chemotherapy based on the accurate HER2-positivity testing for patients with advanced gastric cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, e15075-e15075.	1.6	0
318	HER2 and programmed death-1 ligand-1 (PD-L1) expression in gastric carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e15041-e15041.	1.6	0
319	Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE). <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3662-TPS3662.	1.6	0
320	Aberrations of BUBR1 expression and TP53 gene in human colorectal cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, e14578-e14578.	1.6	0
321	Intratumoral lymphangiogenesis and prognostic significance of VEGFC expression in gastric cancer. <i>Anticancer Research</i> , 2014, 34, 3911-5.	1.1	11
322	Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer. <i>Anticancer Research</i> , 2014, 34, 4207-12.	1.1	11
323	Living donor liver transplantation followed by total gastrectomy—a two-stage planned operative strategy for early gastric cancer concomitant with decompensated liver cirrhosis. <i>Anticancer Research</i> , 2014, 34, 4307-10.	1.1	2
324	Aberrations of BUBR1 and TP53 gene mutually associated with chromosomal instability in human colorectal cancer. <i>Anticancer Research</i> , 2014, 34, 5421-7.	1.1	15

#	ARTICLE	IF	CITATIONS
325	Nuclear expression of chemokine receptor CXCR4 indicates poorer prognosis in gastric cancer. <i>Anticancer Research</i> , 2014, 34, 6397-403.	1.1	25
326	Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study). <i>Anticancer Research</i> , 2014, 34, 6655-62.	1.1	16
327	Outcome of esophagojejunostomy during totally laparoscopic total gastrectomy: a single-center retrospective study. <i>Anticancer Research</i> , 2014, 34, 7227-32.	1.1	15
328	Progression from laparoscopic-assisted to totally laparoscopic distal gastrectomy: comparison of circular stapler (i-DST) and linear stapler (BBT) for intracorporeal anastomosis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 325-332.	2.4	25
329	Surgical Resection for Esophageal Cancer Synchronously or Metachronously Associated with Head and Neck Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 2434-2439.	1.5	17
330	Contribution of BubR1 to oxidative stress-induced aneuploidy in p53-deficient cells. <i>Cancer Medicine</i> , 2013, 2, 447-456.	2.8	11
331	Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2013, 18, 1042-1048.	2.2	40
332	Newly Developed Liver-Retraction Method for Laparoscopic Gastric Surgery Using a Silicone Disc: The Î-Shaped Technique. <i>Journal of the American College of Surgeons</i> , 2013, 216, e43-e46.	0.5	16
333	Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701). <i>Oncology</i> , 2013, 84, 233-239.	1.9	5
334	Multimodal Treatment Strategy for Clinical T3 Thoracic Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 4267-4273.	1.5	21
335	Laparoscopic Gastrectomy for Gastric Cancer with Peritoneal Dissemination after Induction Chemotherapy. <i>Case Reports in Gastroenterology</i> , 2013, 7, 516-521.	0.6	2
336	Significance of the vimentin expression in triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1056-1056.	1.6	3
337	Significance of multimodality therapy for esophageal cancer synchronously or metachronously associated with head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 132-132.	1.6	1
338	Significance of accurate HER2 testing as a new biomarker in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 106-106.	1.6	0
339	A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC0902).. <i>Journal of Clinical Oncology</i> , 2013, 31, 583-583.	1.6	0
340	Phase II study of docetaxel (DTX) and S-1 as neoadjuvant chemotherapy for potentially R0 advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 74-74.	1.6	0
341	S-1/docetaxel compared with the other standard S-1 based regimens as a first-line chemotherapy for patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15173-e15173.	1.6	0
342	A central review of resectability of optimally unresectable colorectal liver metastases following neoadjuvant chemotherapy (KSCC0802).. <i>Journal of Clinical Oncology</i> , 2013, 31, e14633-e14633.	1.6	0

#	ARTICLE	IF	CITATIONS
343	TP53 mutation and BUBR1 overexpression characterize the DNA aneuploidy of gastric cancer.. Journal of Clinical Oncology, 2013, 31, e15039-e15039.	1.6	0
344	Application of splenectomy to decompress portal pressure in left lobe living donor liver transplantation. Fukuoka Acta Medica, 2013, 104, 282-9.	0.1	3
345	Total laparoscopic distal gastrectomy for elderly patients with gastric cancer. Fukuoka Acta Medica, 2013, 104, 290-8.	0.1	3
346	Rendezvous technique treatment for late-onset biliary leakage after major hepatectomy of a living donor: report of a case. Fukuoka Acta Medica, 2013, 104, 309-14.	0.1	0
347	Case of early adenosquamous carcinoma of the stomach. Fukuoka Acta Medica, 2013, 104, 315-20.	0.1	4
348	Differential expression of insulin-like growth factor 1 in human primary liver cancer. Fukuoka Acta Medica, 2013, 104, 334-8.	0.1	2
349	Verification of our therapeutic criterion for acute cholecystitis: "perform a subemergency laparoscopic cholecystectomy when a patient is judged to be able to tolerate general anesthesia"--the experience in a single community hospital. Fukuoka Acta Medica, 2013, 104, 339-43.	0.1	1
350	Suppression of MAL gene expression in gastric cancer correlates with metastasis and mortality. Fukuoka Acta Medica, 2013, 104, 344-9.	0.1	7
351	Significance of stroke volume variation during hepatic resection under infrahepatic inferior vena cava and portal triad clamping. Fukuoka Acta Medica, 2013, 104, 362-9.	0.1	4
352	Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation. Fukuoka Acta Medica, 2013, 104, 376-82.	0.1	0
353	Effect of CD133-positive stem cells in repeated recurrence of hepatocellular carcinoma after liver transplantation: a case report. Fukuoka Acta Medica, 2013, 104, 383-8.	0.1	1
354	Thoracoscopic pericardial drainage for gastric tube ulcer penetrated into the pericardium. Fukuoka Acta Medica, 2013, 104, 389-93.	0.1	1
355	Minimally invasive total pharyng-laryngo-esophagectomy and reconstruction with gastric tube: report of three cases. Fukuoka Acta Medica, 2013, 104, 442-8.	0.1	3
356	Staged operation for synchronous quintuple cancer in the oral cavity, hypopharynx, and esophagus. Esophagus, 2012, 9, 228-233.	1.9	4
357	The Impact of Obesity on the Use of a Totally Laparoscopic Distal Gastrectomy in Patients with Gastric Cancer. Journal of Gastric Cancer, 2012, 12, 108.	2.5	24
358	Clinical aspect and molecular mechanism of DNA aneuploidy in gastric cancers. Journal of Gastroenterology, 2012, 47, 351-358.	5.1	26
359	Loss of Heterozygosity at BRCA1 Locus Is Significantly Associated with Aggressiveness and Poor Prognosis in Breast Cancer. Annals of Surgical Oncology, 2012, 19, 1499-1507.	1.5	11
360	Phase II study of combination therapy with S-1 and cetuximab in patients with KRAS wild-type unresectable colorectal cancer who had previously received irinotecan, oxaliplatin, and fluoropyrimidines (KSCC0901).. Journal of Clinical Oncology, 2012, 30, 3558-3558.	1.6	0

#	ARTICLE	IF	CITATIONS
361	Comparison of efficacy between irinotecan and paclitaxel monotherapy as second- or third-line chemotherapy after S-1 containing regimen for advanced or recurrent gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14722-e14722.	1.6	0
362	Prognostic significance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.. Journal of Clinical Oncology, 2012, 30, e14033-e14033.	1.6	0
363	Neoadjuvant chemoradiotherapy for potentially resectable esophageal squamous cell carcinoma and the significance of Rad51 expression as a factor predictive of the treatment response.. Journal of Clinical Oncology, 2012, 30, e14601-e14601.	1.6	0
364	Surgical Complications and the Risk Factors of Totally Laparoscopic Distal Gastrectomy. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2011, 21, 146-150.	0.8	14
365	Preservation of an Aberrant Hepatic Artery Arising from the Left Gastric Artery during Laparoscopic Gastrectomy for Gastric Cancer. Journal of the American College of Surgeons, 2011, 212, e25-e27.	0.5	17
366	Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. International Journal of Clinical Oncology, 2010, 15, 135-144.	2.2	136
367	The impact of a high-frequency microsatellite instability phenotype on the tumor location-related genetic differences in colorectal cancer. Cancer Genetics and Cytogenetics, 2010, 196, 133-139.	1.0	9
368	High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. Cancer Science, 2010, 101, 639-645.	3.9	55
369	The Difference in p53 Mutations between Cancers of the Upper and Lower Gastrointestinal Tract. Digestion, 2009, 79, 33-39.	2.3	38
370	Phase II Study of Biweekly Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer. Oncology, 2009, 77, 49-52.	1.9	16
371	The triangulating stapling technique for cervical esophagogastric anastomosis after esophagectomy. Surgery Today, 2009, 39, 201-206.	1.5	49
372	Chemosensitivity and Survival in Gastric Cancer Patients with Microsatellite Instability. Annals of Surgical Oncology, 2009, 16, 2510-2515.	1.5	70
373	Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer. World Journal of Gastroenterology, 2009, 15, 2520.	3.3	10
374	Huge Gastric Carcinoma Showing an Exophytic Growth Pattern: A Case Report and Review of the Literature. Journal of Gastrointestinal Cancer, 2008, 39, 42-45.	1.3	0
375	Transient Elastography for the Prediction of Oxaliplatin-Associated Liver Injury in Colon Cancer Patients : A Preliminary Analysis. Journal of Gastrointestinal Cancer, 2008, 39, 82-85.	1.3	12
376	Successful treatment of tracheo mediastinal fistula after tracheal injury obtained during esophagectomy using the pectoralis major muscle: a case report. Esophagus, 2008, 5, 41-44.	1.9	9
377	Advances in esophageal cancer surgery in Japan: An analysis of 1000 consecutive patients treated at a single institute. Surgery, 2008, 143, 499-508.	1.9	155
378	Deregulation of the Akt Pathway in Human Cancer. Current Cancer Drug Targets, 2008, 8, 27-36.	1.6	199

#	ARTICLE	IF	CITATIONS
379	High-resolution fluorescent analysis of microsatellite instability in gastric cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 701-709.	1.6	12
380	p53 Gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: Results in Japan and comparisons with other countries. <i>Cancer Science</i> , 2007, 98, 1152-1156.	3.9	39
381	Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 249-257.	2.5	36
382	Clinical significance of cytokeratin positive cells in bone marrow of gastric cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 995-1000.	2.5	9
383	Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 814-818.	2.8	25
384	Activation of PI3K/Akt signaling and hormone resistance in breast cancer. <i>Breast Cancer</i> , 2006, 13, 137-144.	2.9	182
385	Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 97, 199-203.	2.5	16
386	Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. <i>International Journal of Cancer</i> , 2006, 118, 284-289.	5.1	163
387	Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer. <i>Oncology Reports</i> , 2006, 15, 849-54.	2.6	7
388	Preoperative insertion of transanal ileus tubes for treatment of acute obstruction in cancer of the colon and rectum. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2005, 1, 88-91.	1.1	0
389	Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. <i>International Journal of Cancer</i> , 2005, 117, 376-380.	5.1	170
390	Histological and biological characteristics of esophageal dysplasia. <i>Esophagus</i> , 2005, 2, 129-132.	1.9	0
391	Two modes of microsatellite instability in human cancer: differential connection of defective DNA mismatch repair to dinucleotide repeat instability. <i>Nucleic Acids Research</i> , 2005, 33, 1628-1636.	14.5	55
392	Genetic mutual relationship between PTEN and p53 in gastric cancer. <i>Cancer Letters</i> , 2005, 227, 33-38.	7.2	26
393	Detection of disseminated cancer cells in bone marrow of gastric cancer using real time quantitative reverse transcriptase polymerase chain reaction. <i>Cancer Letters</i> , 2002, 188, 191-198.	7.2	17
394	Frequency of Microsatellite Instability in Breast Cancer Determined by High-Resolution Fluorescent Microsatellite Analysis. <i>Oncology</i> , 2000, 59, 44-49.	1.9	35
395	Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair. <i>Oncogene</i> , 1999, 18, 2143-2147.	5.9	68
396	Clinical significance of micrometastasis in bone marrow of patients with gastric cancer and its relation to angiogenesis. <i>Gastric Cancer</i> , 1999, 2, 46-51.	5.3	15

#	ARTICLE	IF	CITATIONS
397	Precise assessment of microsatellite instability using high resolution fluorescent microsatellite analysis. <i>Nucleic Acids Research</i> , 1997, 25, 3415-3420.	14.5	87
398	Overexpression of the MTA1 gene in gastrointestinal carcinomas: Correlation with invasion and metastasis. <i>International Journal of Cancer</i> , 1997, 74, 459-463.	5.1	151
399	Overexpression of the MTA1 gene in gastrointestinal carcinomas: Correlation with invasion and metastasis. <i>International Journal of Cancer</i> , 1997, 74, 459-463.	5.1	1